• Home

  • Documents

  •  · Vasi hea documentului ,XALKORI (crizotinib) 200mg si 250 mg capsule pentru administrare...
5

 · Vasi hea documentului ,XALKORI (crizotinib) 200mg si 250 mg capsule pentru administrare orala.lncluderea unei noi atentionari referitoare la insuficienta

  • Upload
    lykhue

  • View
    224

  • Download
    0

Embed Size (px)

Citation preview

Page 1:  · Vasi hea documentului ,XALKORI (crizotinib) 200mg si 250 mg capsule pentru administrare orala.lncluderea unei noi atentionari referitoare la insuficienta
Page 2:  · Vasi hea documentului ,XALKORI (crizotinib) 200mg si 250 mg capsule pentru administrare orala.lncluderea unei noi atentionari referitoare la insuficienta
Page 3:  · Vasi hea documentului ,XALKORI (crizotinib) 200mg si 250 mg capsule pentru administrare orala.lncluderea unei noi atentionari referitoare la insuficienta
Page 4:  · Vasi hea documentului ,XALKORI (crizotinib) 200mg si 250 mg capsule pentru administrare orala.lncluderea unei noi atentionari referitoare la insuficienta
Page 5:  · Vasi hea documentului ,XALKORI (crizotinib) 200mg si 250 mg capsule pentru administrare orala.lncluderea unei noi atentionari referitoare la insuficienta

CRIZOTINIB EN CANCER DE PULMÓN NO MICROCÍTICO: …

CRIZOTINIB EN CANCER DE PULMÓN NO MICROCÍTICO: …

Documents
Therapeutic strategies to overcome crizotinib resistance ... · Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene

Therapeutic strategies to overcome crizotinib resistance ... · Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene

Documents
Annual Review 2013 - Pfizer Annual Review 2013 1 ... (methylphenidate HCl) Eliquis (apixaban) Xalkori (crizotinib) Xeljanz (tofacitinib) Inlyta (axitinib)

Annual Review 2013 - Pfizer Annual Review 2013 1 ... (methylphenidate HCl) Eliquis (apixaban) Xalkori (crizotinib) Xeljanz (tofacitinib) Inlyta (axitinib)

Documents
Avelumab (anti PD-L1) in combination with crizotinib or ... · Avelumab (anti–PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC:

Avelumab (anti PD-L1) in combination with crizotinib or ... · Avelumab (anti–PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC:

Documents
Xalkori Kapsul

Xalkori Kapsul

Documents
cardiaca aparuta la... · includerea unei noi atentionari referitoare la insuficienta cardiaca aparuta la pacientii tratati cu medicamentul XALKORI (crizotinib). Vä rugäm sä luati

cardiaca aparuta la... · includerea unei noi atentionari referitoare la insuficienta cardiaca aparuta la pacientii tratati cu medicamentul XALKORI (crizotinib). Vä rugäm sä luati

Documents
Attachment: Product Information: Crizotinib · Web viewAttachment 1: Product information AusPAR Xalkori Pfizer Australia Pty Ltd PM-2016-03535-1-4 Final 18 October 2018.This Product

Attachment: Product Information: Crizotinib · Web viewAttachment 1: Product information AusPAR Xalkori Pfizer Australia Pty Ltd PM-2016-03535-1-4 Final 18 October 2018.This Product

Documents
Crizotinib Synergizes with Chemotherapy in Preclinical ...clincancerres.aacrjournals.org/content/clincanres/22/4/948.full.pdf · Crizotinib Synergizes with Chemotherapy in ... The

Crizotinib Synergizes with Chemotherapy in Preclinical ...clincancerres.aacrjournals.org/content/clincanres/22/4/948.full.pdf · Crizotinib Synergizes with Chemotherapy in ... The

Documents
EML4-ALK translocations and crizotinib

EML4-ALK translocations and crizotinib

Documents
CRIZOTINIB NELLA NEOPLASIA POLMONARE

CRIZOTINIB NELLA NEOPLASIA POLMONARE

Documents
TRATAMIENTO INDIVIDUALIZADO CON TKIs EN … · Kinase domain Signaling via the ALK Mutant Fusion Proteins •Crizotinib es un Inhibidor tirosin-kinasa dual de ALK y c-Met oral Crizotinib

TRATAMIENTO INDIVIDUALIZADO CON TKIs EN … · Kinase domain Signaling via the ALK Mutant Fusion Proteins •Crizotinib es un Inhibidor tirosin-kinasa dual de ALK y c-Met oral Crizotinib

Documents
XALKORI, INN-crizotinib

XALKORI, INN-crizotinib

Documents
Xalkori® crizotinibe I - pfizer.com.br · LLD_Bra_CDSv21.0_16Aug2017_v1_XALCAP_15_VPS 24/ago/2017 1 Xalkori® crizotinibe I - IDENTIFICAÇÃO DO MEDICAMENTO Nome …

Xalkori® crizotinibe I - pfizer.com.br · LLD_Bra_CDSv21.0_16Aug2017_v1_XALCAP_15_VPS 24/ago/2017 1 Xalkori® crizotinibe I - IDENTIFICAÇÃO DO MEDICAMENTO Nome …

Documents
A TIMELINE OF XALKORI · The XALKORI label is updated to include data from PROFILE 1014. 2014 Crizotinib (XALKORI) receives a category 1 National Comprehensive Cancer Network ® (NCCN

A TIMELINE OF XALKORI · The XALKORI label is updated to include data from PROFILE 1014. 2014 Crizotinib (XALKORI) receives a category 1 National Comprehensive Cancer Network ® (NCCN

Documents
NAME OF THE MEDICINAL PRODUCT QUALITATIVE AND …ioni.pom.go.id/sites/default/files/obat_baru/xalkori.pdfCrizotinib Tradename: XALKORI NAME OF THE MEDICINAL PRODUCT XALKORI 250 mg;

NAME OF THE MEDICINAL PRODUCT QUALITATIVE AND …ioni.pom.go.id/sites/default/files/obat_baru/xalkori.pdfCrizotinib Tradename: XALKORI NAME OF THE MEDICINAL PRODUCT XALKORI 250 mg;

Documents
MÉDICAMENTS CIBLANT ALK : CRIZOTINIB, CÉRITINIB

MÉDICAMENTS CIBLANT ALK : CRIZOTINIB, CÉRITINIB

Documents
cMET inhibitor crizotinib impairs angiogenesis and reduces tumor

cMET inhibitor crizotinib impairs angiogenesis and reduces tumor

Documents
ATENTIONARI SI CONTRAINDICATII in Folosirea Remediilor Naturiste

ATENTIONARI SI CONTRAINDICATII in Folosirea Remediilor Naturiste

Documents
Development of Crizotinib for the Treatment of ALK .../media/Files/Activity Files/Research... · Crizotinib in the ALK ATP binding pocket 2. Contemporaneous Regulatory Approvals

Development of Crizotinib for the Treatment of ALK .../media/Files/Activity Files/Research... · Crizotinib in the ALK ATP binding pocket 2. Contemporaneous Regulatory Approvals

Documents
XALKORI (crizotinib) Is Available Through Specialty … 610020 GROUP: 99992415 ID#: XXXXXXXXXXX EXPIRATION DATE: 12/31/2014 Limits, terms, and conditions apply. Thiscardisnothealth

XALKORI (crizotinib) Is Available Through Specialty … 610020 GROUP: 99992415 ID#: XXXXXXXXXXX EXPIRATION DATE: 12/31/2014 Limits, terms, and conditions apply. Thiscardisnothealth

Documents
Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a ...luciferase-labeled uveal melanoma cells transplanted by retro-orbital injections to test the effect of crizotinib on metastasis

Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a ...luciferase-labeled uveal melanoma cells transplanted by retro-orbital injections to test the effect of crizotinib on metastasis

Documents
CRIZOTINIB-RESISTANT NPM-ALK MUTANTS CONFER DIFFERENTIAL ... · Facoltà di Medicina e Chirurgia PhD in Ematologia Sperimentale, XXIV ciclo CRIZOTINIB-RESISTANT NPM-ALK MUTANTS CONFER

CRIZOTINIB-RESISTANT NPM-ALK MUTANTS CONFER DIFFERENTIAL ... · Facoltà di Medicina e Chirurgia PhD in Ematologia Sperimentale, XXIV ciclo CRIZOTINIB-RESISTANT NPM-ALK MUTANTS CONFER

Documents
ALK IN LUNG CANCER ROS1 IN LUNG CANCER NSCLC CLINICAL …crizotinib)_Fact_Sheet... · – Fatal adverse events in XALKORI-treated patients occurred in 2.3% of patients, consisting

ALK IN LUNG CANCER ROS1 IN LUNG CANCER NSCLC CLINICAL …crizotinib)_Fact_Sheet... · – Fatal adverse events in XALKORI-treated patients occurred in 2.3% of patients, consisting

Documents
PathoBasic Molekularpathologie Teil 1 · Vemurafenib (Zelboraf) B-Raf Melanoma Crizotinib (Xalkori) EML4/ALK, Met NSCLC Vandetanib (Caprelsa) EGFR, VEGFR, Ret TyroidCa mTor-Hemmer

PathoBasic Molekularpathologie Teil 1 · Vemurafenib (Zelboraf) B-Raf Melanoma Crizotinib (Xalkori) EML4/ALK, Met NSCLC Vandetanib (Caprelsa) EGFR, VEGFR, Ret TyroidCa mTor-Hemmer

Documents
Crizotinib en cáncer de pulmón no microcítico

Crizotinib en cáncer de pulmón no microcítico

Health & Medicine
crizotlnlb)-atentionari insuficienta... · cu crizotinib peste 14700 de pacienti, insuficienta cardiac' la 40 (frecventå de raportare: 0.27%). mgjoritatea caurilor, aceasta a apArut

crizotlnlb)-atentionari insuficienta... · cu crizotinib peste 14700 de pacienti, insuficienta cardiac' la 40 (frecventå de raportare: 0.27%). mgjoritatea caurilor, aceasta a apArut

Documents
Leading In Biopharmaceutical Innovation...cell lung cancer (NSCLC). These data established Xalkori as a standard of care for this patient population. Xalkori also has received conditional

Leading In Biopharmaceutical Innovation...cell lung cancer (NSCLC). These data established Xalkori as a standard of care for this patient population. Xalkori also has received conditional

Documents
Recomandari Si Atentionari

Recomandari Si Atentionari

Documents
décembre 2017 AcSéAcSe Crizotinib n°8 · Etude de phase 1b de crizotinib dans les tumeurs avec activation de ALK ... Pr Gilles VASSAL Coordonnateur AcSé Crizotinib Gustave Roussy

décembre 2017 AcSéAcSe Crizotinib n°8 · Etude de phase 1b de crizotinib dans les tumeurs avec activation de ALK ... Pr Gilles VASSAL Coordonnateur AcSé Crizotinib Gustave Roussy

Documents
Crizotinib Induces PUMA-Dependent Apoptosis in Colon ...€¦ · Crizotinib Induces PUMA-Dependent Apoptosis in Colon Cancer Cells Xingnan Zheng1, Kan He1, Lin Zhang2, and Jian Yu1

Crizotinib Induces PUMA-Dependent Apoptosis in Colon ...€¦ · Crizotinib Induces PUMA-Dependent Apoptosis in Colon Cancer Cells Xingnan Zheng1, Kan He1, Lin Zhang2, and Jian Yu1

Documents